DT&CRO CO., Ltd. (KOSDAQ:383930)

Market Cap	39.69B
Revenue (ttm)	39.50B
Net Income (ttm)	-1.64B
Shares Out	12.78M
EPS (ttm)	-401.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,770
Average Volume	102,852
Open	3,095.00
Previous Close	3,095.00
Day's Range	3,090.00 - 3,220.00
52-Week Range	3,045.00 - 9,370.00
Beta	3.35
RSI	26.21
Earnings Date	n/a

About Perficient

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. It conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 383930

Financial Performance

In 2024, DT&CRO CO.'s revenue was 35.97 billion, an increase of 35.30% compared to the previous year's 26.59 billion. Losses were -2.00 billion, -87.98% less than in 2023.